HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV)

HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV)

HLA-A*0201 & B2M & NY-ESO-1 (SLLMWITQV) Product List

Species
  • Human(5)
Tag
  • Flag Tag & Avi Tag(2)
  • His Tag(2)
  • Flag Tag(1)
Host
  • HEK293(5)
Conjugate
  • Unconjugated(2)
  • APC Labeled(1)
  • Biotin-labeled(1)
  • PE Labeled(1)
Grade
  • RUO(5)
Low Endotoxin
  • No(5)
You Have Viewed 1-5 Of 5 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
ATL-1102ATL-1102; ATL/TV-1102; ISIS-107248; TV-1102Phase 2 ClinicalIonis Pharmaceuticals Inc
Multiple Sclerosis; Muscular Dystrophy, Duchenne
Details
BIIB-107(Biogen)BIIB-107Phase 1 ClinicalBiogen Inc
Multiple Sclerosis
Details
ELND-004ELND-004Phase 1 ClinicalPerrigo Company Plc
Autoimmune Diseases
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Natalizumab biosimilar(Polpharma Biologics)PB-006; DST-356A1ApprovedPolpharma Biologics SaTyrukoUnited StatesCrohn Disease; Multiple SclerosisSandoz Inc2023-08-24
Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease
Details
Customer Reviews